Clinical Trial Update: Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia [Phase 2]

View source ↗

Summary

Phase 2 trial of high-dose lenalidomide in myelodysplastic syndrome (MDS) with trilineage dysplasia; study terminated with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Myelodysplastic Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2018-10-17